Macrozyme Announces a Collaboration with Genzyme Corporation in

Document Sample
Macrozyme Announces a Collaboration with Genzyme Corporation in Powered By Docstoc
					                  Macrozyme Announces a Collaboration
                  with Genzyme Corporation in Diabetes
                      and Other Possible Indications
Amsterdam, November 24, 2005.

Macrozyme today announced that it has entered into a collaboration agreement with
Genzyme Corporation, Cambridge, Massachusetts. The exclusive collaboration will
explore the applications of Macrozyme’s library of small molecules as new potent
inhibitors of glucosylceramide synthase, specifically within the field of diabetes and
insulin resistance, along with other possible indications. The library of compounds was
discovered and developed by Hans Aerts, Professor of Medical Biochemistry at the
Academic Medical Center in Amsterdam, The Netherlands. Terms of the agreement
involve royalties and milestone payments, as well as research funding to Macrozyme.

"This collaboration with Genzyme is an important milestone for Macrozyme" said Chief
Executive Officer Edward van Wezel. “Both companies have a strong expertise and
focus on metabolic disorders, and Genzyme has an excellent development track record
which we believe will enhance the success of the clinical development of a first lead
product."

“Various compounds have already shown intriguing results in the decrease of insulin
resistance in preclinical models,” said Professor Hans Aerts, Chief Scientific Officer and
co-founder of Macrozyme. “We look forward to the potential for initiating clinical trials in
the near future.”

Macrozyme’s library of compounds is understood to inhibit the glycosphingolipid
biosynthesis pathway. High levels of glycosphingolipid are known to be associated with
insulin resistance and diabetes.

Diabetes affects over 100 million people worldwide, and is one of the most common
chronic conditions in the Western world. The prevalence has tripled in the last 30 years,
and much of the increase is due to the dramatic upsurge in obesity. It is most common in
adults over age 40, with a growing number of children afflicted, and is associated with
obesity, family history of diabetes, and certain racial and ethnic backgrounds.

About Macrozyme
Macrozyme B.V. was founded in 2001 as a spin-off from the Academic Medical Center,
Amsterdam. The company focuses on the development of new proprietary compounds
discovered by Professor Hans Aerts and his group for the treatment of diabetes,
inflammatory disorders and lysosomal storage diseases. Macrozyme’s research
activities concentrate on the role of glycolipid metabolism in various diseases. For more
information, please visit www.macrozyme.com


About Genzyme Corporation
One of the world's leading biotechnology companies, Genzyme is dedicated to making a
major positive impact on the lives of people with serious diseases. Founded in 1981,
Genzyme has grown from a small start-up to a diversified enterprise with 2004 revenues
of $2.2 billion and more than 8,000 employees in locations spanning the globe. With
many established products and services helping patients in more than 80 countries,
Genzyme is a leader in the effort to develop and apply the most advanced technologies
in the life sciences. The company's products and services are focused on rare inherited
disorders, kidney disease, orthopaedics, cancer, transplant and immune diseases, and
diagnostic testing. Genzyme's commitment to innovation continues today with a
substantial development program focused on these fields as well as heart disease and
other areas of unmet medical need. For more information, please visit
www.genzyme.com.


Contact:
Macrozyme B.V.
Edward C. van Wezel, MSc.
Chief Executive Officer
Tel.: + 31 (0) 20 5667867
Fax: +31 (0) 20 5669168
e.vanwezel@macrozyme.com